$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Safety and Efficacy Study of DCVax-Direct in Solid Tumors

2013-06

2016-12

N/A

60

Study Overview

Safety and Efficacy Study of DCVax-Direct in Solid Tumors

The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct into selected solid tissue tumors has the ability to reduce tumor growth.

N/A

  • Locally Advanced Tumor
  • Metastatic Solid Tissue Tumors
  • Liver Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Melanoma
  • BIOLOGICAL: DCVax-Direct
  • NWBio 050012

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2013-06-14  

N/A  

2015-10-06  

2013-06-20  

N/A  

2015-10-07  

2013-06-21  

N/A  

2015-10  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: DCVax-Direct

DCVax-Direct: autologous, activated dendritic cells for intratumoral injection

BIOLOGICAL: DCVax-Direct

  • Autologous, activated dendritic cells for intratumoral injection
Primary Outcome MeasuresMeasure DescriptionTime Frame
Number of patients with adverse events6 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Number of patients with tumor response18 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria (summary):

  • Age between 18 and 75 years (inclusive) at screening.
  • Karnofsky performance status (KPS) of 70 or higher or Eastern Cooperative Oncology Group (ECOG) 0-1 at screening.
  • Subjects with a histological or cytopathological confirmed diagnosis of a locally advanced or metastatic solid tumor malignancy for which primary treatment is no longer effective or does not offer curative or life-prolonging potential per clinician judgment, with the understanding that DCVax-Direct is not intended as a treatment of last resort.
  • Not eligible for complete resection due to either tumor location, physician's assessment or subject's choice.
  • Must have completed at least one recent treatment regimen in the metastatic or advanced setting in the disease currently under treatment to reduce tumor burden.
  • Any steroid therapy >2 mg dexamethasone or equivalent dose should be stopped or have been tapered down 2 weeks prior to the leukapheresis.
  • At least one measurable tumor mass, i.e. a lesion that can accurately be measured by CT/MRI in at least one dimension with longest diameter ≥ 1 cm, that is accessible for injection either with or without imaging (CT/ultrasound) guidance.
  • Adequate hematological, hepatic, and renal function,
  • Adequate blood coagulation parameters
  • Life expectation of >3 months.

    • Exclusion Criteria (Summary):

  • Positive HIV-1, HIV-2, or Human T-lymphotropic virus (HTLV-I/II) tests.
  • History of current or prior (within the last two years) active clinically significant malignancy other than the tumor type for which DCVax-Direct treatment is considered, and except for primary tumor in the case of metastases and adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • Heavily pretreated (HP) subjects are not eligible for this study, unless treatments have occurred more than 1 year in the past.
  • Presence of brain metastases, unless treated surgically and/or irradiated and clinically stable off steroids or on low dose (< 2 mg per day) steroids for ≥ 14 days, or presence of leptomeningeal disease.
  • History of immunodeficiency or unresolved autoimmune disease.
  • Requirement for ongoing immunosuppressants.
  • Prior active immunotherapy for cancer within the past 2 years.
  • Ongoing medical need for continuous anti-coagulation or anti-platelet medication.
  • Known genetic cancer-susceptibility syndromes.
  • Acute or active uncontrolled infection
  • Ongoing fever ≥ 101.5 degrees F/38.6 degrees C at screening.
  • Unstable or severe intercurrent medical conditions such as unstable angina, uncontrolled arrhythmias, Crohn's Disease, ulcerative colitis etc.
  • Females of child-bearing potential who are pregnant or lactating or who are not using adequate contraception (surgical, hormonal or double barrier, i.e. condom and diaphragm).
  • Allergy or anaphylaxis to any of the reagents used in this study.
  • Inability to obtain informed consent because of psychiatric or complicating medical problems.
  • Inability or unwillingness to return for required visits and follow-up exams.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • STUDY_DIRECTOR: Marnix Bosch, MBA, PhD, Northwest Biotherapeutics

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    NPCF Pop up

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate